Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy

被引:49
作者
Marshall, Leslie J. [1 ]
Major, Eugene O. [1 ]
机构
[1] NINDS, Lab Mol Med & Neurosci, Mol Med & Virol Sect, NIH, Bethesda, MD 20892 USA
关键词
JC virus; progressive multifocal leukoencephalopathy; virus latency; virus tropism; molecular regulation; host cell-virus interactions; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN POLYOMAVIRUS JC; NUCLEAR FACTOR-I; OF-THE-LITERATURE; HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW-TRANSPLANTATION; HUMAN NEUROTROPIC VIRUS; DNA-BINDING PROTEIN; TRANSCRIPTIONAL CONTROL REGION; REMITTING MULTIPLE-SCLEROSIS;
D O I
10.1007/s11481-010-9203-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Progressive multifocal leukoencephalopathy (PML) is a growing concern for patients undergoing immune modulatory therapies for treatment of autoimmune diseases such as multiple sclerosis. Currently, there are no drugs approved for the treatment of PML that have been demonstrated in the patient to effectively and reproducibly alter the course of disease progression. The human polyoma virus JC is the causative agent of PML. JC virus (JCV) dissemination is tightly controlled by regulation of viral gene expression from the promoter by cellular transcription factors expressed in cells permissive for infection. JCV infection likely occurs during childhood, and latent virus containing PML-associated promoter sequences is maintained in lymphoid cells within the bone marrow. Because development of PML is tightly linked to suppression and or modulation of the immune system as in development of hematological malignancies, AIDS, and monoclonal antibody treatments, further scrutiny of the course of JCV infection in immune cells will be essential to our understanding of development of PML and identification of new therapeutic targets.
引用
收藏
页码:404 / 417
页数:14
相关论文
共 209 条
  • [1] Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside
    Aksamit, AJ
    [J]. JOURNAL OF NEUROVIROLOGY, 2001, 7 (04) : 386 - 390
  • [2] Alla P, 2001, PRESSE MED, V30, P1498
  • [3] Identification of a third human polyomavirus
    Allander, Tobias
    Andreasson, Kalle
    Gupta, Shawon
    Bjerkner, Annelie
    Bogdanovic, Gordana
    Persson, Mats A. A.
    Dalianis, Tina
    Ramqvist, Torbjorn
    Andersson, Bjorn
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (08) : 4130 - 4136
  • [4] The atypical antipsychotic agents zisprasidone, risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephatopathy
    Altschuler, EL
    Kast, RE
    [J]. MEDICAL HYPOTHESES, 2005, 65 (03) : 585 - 586
  • [5] AMEMIYA K, 1992, J BIOL CHEM, V267, P14204
  • [6] AMEMIYA K, 1989, J BIOL CHEM, V264, P7025
  • [7] OVEREXPRESSION AND REACTIVATION OF BINDING-ACTIVITY OF THE RECOMBINANT CTF/NF-1 TRANSCRIPTION FACTOR
    AMEMIYA, K
    DURHAM, L
    MAJOR, EO
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 1994, 5 (01) : 57 - 64
  • [8] ANTINORI A, 1994, AIDS, V8, P1022, DOI 10.1097/00002030-199407000-00030
  • [9] Progressive multifocal leukoencephalopathy and chronic lymphocytic leukemia.
    Attout, H
    Rahmeh, F
    Lehuede, G
    Girardel, M
    Ziegler, F
    [J]. REVUE DE MEDECINE INTERNE, 2000, 21 (08): : 698 - 700
  • [10] INTERACTION OF THE HUMAN POLYOMAVIRUS, JCV, WITH HUMAN LYMPHOCYTES-B
    ATWOOD, WJ
    AMEMIYA, K
    TRAUB, R
    HARMS, J
    MAJOR, EO
    [J]. VIROLOGY, 1992, 190 (02) : 716 - 723